



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

产品名称: **ML-213**  
产品别名: **ML-213**

生物活性:				
Description	ML213 is a selective activator of Kv7.2 and Kv7.4 channels, enhances Kv7.2 and Kv7.4 channels with EC <sub>50</sub> s of 230 and 510 nM, respectively.			
IC <sub>50</sub> & Target	EC <sub>50</sub> : 230 nM (Kv7.2 channel), 510 nM (Kv7.4 channel)[2][3]			
In Vitro	ML213 (100 nM-30 μM) increases maximal conductance to a peak at 212% ± 27% of control, with an EC <sub>50</sub> of 0.8 ± 0.3 μM. ML213 (10 μM) reduces the deactivation rates of Kv7.4 currents by 4.6-fold in the voltage range from -130 mV to -90 mV. ML213 is a potent and effective activator of homomeric Kv7.5 channels overexpressed in A7r5 cells. ML213 increases maximal conductance of Kv7.5 channels with an EC <sub>50</sub> of 0.7 ± 0.2 μM. ML213 (10 μM) also reduces deactivation rates of Kv7.5 currents by 5.9-fold on average. ML213 produces similar effects on heteromeric Kv7.4/7.5 channels: 204% ± 11% maximal increase in conductance with an EC <sub>50</sub> of 1.1 ± 0.6 μM and a 34.2 ± 3.3 mV maximal negative shift of the activation curve, with an EC <sub>50</sub> of 3.8 ± 1.2 μM[1]. ML213 causes a vasorelaxation in different precontracted rat blood vessels. ML213 (10 μM) also hyperpolarizes mesenteric artery smooth muscle cells[2]. ML213 causes a concentration-dependent shift in the V <sub>1/2</sub> for KCNQ2 activation with an EC <sub>50</sub> 340 ± 70 nM and a maximal shift of 37.4 mV[3].			
Solvent&Solubility	<b>In Vitro:</b> <b>DMSO : 30 mg/mL (116.56 mM; Need ultrasonic and warming)</b>			
	Preparing Stock Solutions	<div>Solvent Mass Concentration</div>	1 mg	5 mg
		1 mM	3.8855 mL	19.4273 mL
		5 mM	0.7771 mL	3.8855 mL
		10 mM	0.3885 mL	1.9427 mL
	*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液, 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限: -80℃, 6 months; -20℃, 1 month。 -80℃ 储存时, 请在 6 个月内使用, -20℃ 储存时, 请在 1 个月内使用。			
References	[1]. Brueggemann LI, et al. Differential activation of vascular smooth muscle Kv7.4, Kv7.5, and Kv7.4/7.5 channels by ML213 and ICA-069673. Mol Pharmacol. 2014 Sep;86(3):330-41. [2]. Jepps TA, et al. Vasorelaxant effects of novel Kv 7.4 channel enhancers ML213 and NS15370. Br J Pharmacol. 2014 Oct;171(19):4413-24. [3]. Yu H, et al. Discovery, Synthesis, and Structure Activity Relationship of a Series of N-Aryl-bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener. ACS Chem Neurosci. 2011 Oct 19;2(10):572-577.			